Abstract
The most common treatments for infectious diseases target the invading pathogen. The efficacy of such an approach may, however, be countered by the possibility of the development of resistance to a pharmacophore, through mutation(s) in pathogen molecules required for activity. Given the fact that pathogens exploit host factors in order to grow in an otherwise hostile environment, one possible way to circumvent the emergence of resistance is to develop drugs that target non-essential host factors hijacked by the pathogen, rather than the pathogen’s own molecules. Such solutions are already being developed for various viral and bacterial pathogens, but much less has been achieved with infections caused by protozoan parasites, as is the case of Plasmodium. Here, we highlight recent progress in host target-based anti-viral and anti-bacterial approaches and discuss possible host targets that may be used for anti-malarial interventions. Host molecules that play a role during either the liver or the blood stage of Plasmodium infection are outlined and their potential merits as anti-malarial targets are discussed.
Keywords: Malaria, Plasmodium, host factors, host targets, hepatitis C virus, liver-stage, blood-stage, drug resistance
Current Pharmaceutical Design
Title:Targeting Host Factors to Circumvent Anti-Malarial Drug Resistance
Volume: 19 Issue: 2
Author(s): Miguel Prudencio and Maria M. Mota
Affiliation:
Keywords: Malaria, Plasmodium, host factors, host targets, hepatitis C virus, liver-stage, blood-stage, drug resistance
Abstract: The most common treatments for infectious diseases target the invading pathogen. The efficacy of such an approach may, however, be countered by the possibility of the development of resistance to a pharmacophore, through mutation(s) in pathogen molecules required for activity. Given the fact that pathogens exploit host factors in order to grow in an otherwise hostile environment, one possible way to circumvent the emergence of resistance is to develop drugs that target non-essential host factors hijacked by the pathogen, rather than the pathogen’s own molecules. Such solutions are already being developed for various viral and bacterial pathogens, but much less has been achieved with infections caused by protozoan parasites, as is the case of Plasmodium. Here, we highlight recent progress in host target-based anti-viral and anti-bacterial approaches and discuss possible host targets that may be used for anti-malarial interventions. Host molecules that play a role during either the liver or the blood stage of Plasmodium infection are outlined and their potential merits as anti-malarial targets are discussed.
Export Options
About this article
Cite this article as:
Prudencio Miguel and M. Mota Maria, Targeting Host Factors to Circumvent Anti-Malarial Drug Resistance, Current Pharmaceutical Design 2013; 19 (2) . https://dx.doi.org/10.2174/1381612811306020290
DOI https://dx.doi.org/10.2174/1381612811306020290 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regulation of Multidrug Resistance by Pro-Inflammatory Cytokines
Current Cancer Drug Targets Transcending the Cutaneous Barrier Through Nanocarrier Exploration for Passive Delivery of Anti-hypertensive Drugs: A Critical Review
Recent Patents on Nanotechnology Targeting the Bone Microenvironment in Metastatic Castration-Resistant Prostate Cancer
Current Drug Targets Risk Factors for Ischemic Heart Disease
Reviews on Recent Clinical Trials Difference in the Influence of the Lipid Profile as a Coronary Risk Factor in Patients with and Without Diabetes Mellitus
Vascular Disease Prevention (Discontinued) Plasma VEGF and IL-8 Levels in Patients with Mixed Dyslipidaemia. Effect of Rosuvastatin Monotherapy or its Combination at a Lower Dose with Omega-3 Fatty Acids: A Pilot Study
Current Vascular Pharmacology Prodrug Strategies for Antihypertensives
Current Topics in Medicinal Chemistry Molecular Interaction and Computational Analytical Studies of Pinocembrin for its Antiangiogenic Potential Targeting VEGFR-2: A Persuader of Metastasis
Medicinal Chemistry Nitric Oxide: News from Stem Cells to Platelets
Current Medicinal Chemistry Nitric Oxide and Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Impact of Immunosuppressive Drugs on the Development of Cardiac Allograft Vasculopathy
Current Vascular Pharmacology Perfect 24-hr Blood Pressure Control: Up-to-Date 2020
Current Hypertension Reviews Statins and Left Ventricular Function
Current Pharmaceutical Design Challenges and Controversies in Autoantibodies Associated with Systemic Rheumatic Diseases
Current Rheumatology Reviews The Fabry Cardiomyopathy - Diagnostic Approach and Current Treatment
Current Pharmaceutical Design Metabolic Syndrome Racial Differences in Adolescents
Current Diabetes Reviews Managing Comorbidity in COPD: A Difficult Task
Current Drug Targets Humanin: A Possible Linkage Between Alzheimer’s Disease and Type 2 Diabetes
CNS & Neurological Disorders - Drug Targets Evaluation of Tophaceous Gout by FDG-PET/CT and Bone Scan
Current Molecular Imaging (Discontinued) The Epithelial Na+ Channel as a Determinant of Blood Pressure
Current Hypertension Reviews